EXAS—(+25%)—says “adjusted EBITDA” was positive in 4Q22 and will be positive in every quarter of 2023: https://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-204500863.html Despite robust sales growth for Cologuard, EXAS has not yet turned profitable according to GAAP.